Our data, analyzed in the context of the existing literature, suggest that increased levels of SIRT1 and HES1 in RNA of peripheral blood cells of stable CAD/COPD patients may be part of the protective action of ticagrelor. The gene discussed is HES1; the disease is coronary artery disorder.